JSPR

Company Overview — What Does Jasper Therapeutics, Inc. Do?

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California. Jasper Therapeutics, Inc. (JSPR) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Ronald A. Martell and employs approximately 20 people. With a market capitalization of $22M, JSPR is one of the notable companies in the Healthcare sector.

Jasper Therapeutics, Inc. (JSPR) Stock Rating — Avoid (April 2026)

As of April 2026, Jasper Therapeutics, Inc. receives a Avoid rating with a composite score of 16.7/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.JSPR ranks #4,413 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Jasper Therapeutics, Inc. ranks #829 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

JSPR Stock Price and 52-Week Range

Jasper Therapeutics, Inc. (JSPR) currently trades at $0.82. The stock lost $0.01 (0.6%) in the most recent trading session. The 52-week high for JSPR is $7.19, which means the stock is currently trading -88.6% from its annual peak. The 52-week low is $1.11, putting the stock -26.3% above its annual trough. Recent trading volume was 801K shares, suggesting relatively thin trading activity.

Is JSPR Overvalued or Undervalued? — Valuation Analysis

Jasper Therapeutics, Inc. (JSPR) carries a value factor score of 7/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.50x, versus the sector average of 2.75x.

At current multiples, Jasper Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Jasper Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Jasper Therapeutics, Inc. (JSPR) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -2055.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -238.5% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

JSPR Debt, Balance Sheet, and Financial Health

Jasper Therapeutics, Inc. has a debt-to-equity ratio of 762.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 2.62x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $51M.

JSPR has a beta of 1.10, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Jasper Therapeutics, Inc. is 24/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Jasper Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Jasper Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.95. Net income for the quarter was $-85M. Operating income came in at $-88M.

In FY 2025, Jasper Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.95. Net income for the quarter was $-76M. Operating income came in at $-84M.

In Q3 2025, Jasper Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.13. Net income for the quarter was $-19M. Operating income came in at $-19M.

In Q2 2025, Jasper Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.74. Net income for the quarter was $-27M. Operating income came in at $-27M.

Over the past 8 quarters, Jasper Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing JSPR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

JSPR Dividend Yield and Income Analysis

Jasper Therapeutics, Inc. (JSPR) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

JSPR Momentum and Technical Analysis Profile

Jasper Therapeutics, Inc. (JSPR) has a momentum factor score of 9/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 55/100 reflects moderate short selling activity.

JSPR vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Jasper Therapeutics, Inc. (JSPR) ranks #829 out of 838 stocks based on the Blank Capital composite score. This places JSPR in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing JSPR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full JSPR vs S&P 500 (SPY) comparison to assess how Jasper Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

JSPR Next Earnings Date

No upcoming earnings date has been announced for Jasper Therapeutics, Inc. (JSPR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy JSPR? — Investment Thesis Summary

The quantitative profile for Jasper Therapeutics, Inc. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 7/100 indicates premium valuation. Momentum is weak at 9/100, a headwind for near-term performance. High volatility (stability score 24/100) increases portfolio risk.

In summary, Jasper Therapeutics, Inc. (JSPR) earns a Avoid rating with a composite score of 16.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on JSPR stock.

Related Resources for JSPR Investors

Explore more research and tools: JSPR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare JSPR head-to-head with peers: JSPR vs AZN, JSPR vs SLGL, JSPR vs VMD.